Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
10.31
Nov 18 • 3:59 PM ET Dollar change-0.40 Percentage change(-3.73%)
Aftermarket Close
10.31
Aftermarket • 4:00 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
630.80M
Enterprise Value
-294.54M
Income
-99.85M
Sales
23.29M
Book/sh
14.90
Cash/sh
15.46
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
109
IPO
Jun 11, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
27.08
P/B
0.69
P/C
0.67
P/FCF
-
EV/EBITDA
-
EV/Sales
-12.65
Quick Ratio
17.69
Current Ratio
17.69
Debt/Eq
0.02
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
-1.59
EPS next Y
-2.54
EPS next Q
-0.52
EPS this Y
10.62%
EPS next Y
-55.25%
EPS next 5Y
-19.81%
EPS past 3/5Y
-6.44% -62.26%
Sales past 3/5Y
5.11% -
EPS Y/Y TTM
4.85%
Sales Y/Y TTM
132.89%
EPS Q/Q
12.78%
Sales Q/Q
-7.11%
Insider Own
5.41%
Insider Trans
-0.12%
Inst Own
96.94%
Inst Trans
1.81%
ROA
-9.94%
ROE
-10.58%
ROIC
-10.74%
Gross Margin
92.02%
Oper. Margin
-599.26%
Profit Margin
-428.74%
SMA20
-31.30%
SMA50
-36.54%
SMA200
-32.66%
Trades
Shs Outstand
61.17M
Shs Float
57.87M
52W High
35.34 -70.83%
52W Low
10.50 -1.81%
Volatility
5.07% 7.69%
ATR (14)
1.06
RSI (14)
26.01
Beta
2.52
Rel Volume
1.03
Avg Volume
952.53K
Volume
976,346
Perf Week
-16.79%
Perf Month
-40.06%
Perf Quarter
-40.34%
Perf Half Y
-28.40%
Perf YTD
-25.29%
Perf Year
-64.47%
Perf 3Y
18.78%
Perf 5Y
-45.77%
Perf 10Y
-
Prev Close
10.71
Price
10.31
Change %
-3.73%
Consensus
Buy
Avg. Price Target
$31.87
Implied Upside
+209.1%
Analysts14incl. previous ratings
Rating Distribution10 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2026Downgrade
WWolfe Research
Outperform → Peer Perform
Aug 24, 2026Upgrade
WWolfe Research
Peer Perform → Outperform$23+123.1%
Apr 20, 2026Downgrade
BCS logoBBarclays
Overweight → Underweight$14+35.8%
Apr 15, 2026Downgrade
UBS logoUUBS
Buy → Neutral$15+45.5%
Nov 18, 2025Initiated
WWolfe Research
Peer Perform
Sep 17, 2025Initiated
BCS logoBBarclays
Overweight$47+355.9%
Sep 10, 2025Initiated
TFC logoTTruist
Buy$100+869.9%
Sep 10, 2025Initiated
SF logoSStifel
Buy$45+336.5%
Sep 04, 2025Initiated
GGuggenheim
Buy$72+598.4%
Aug 19, 2025Initiated
PPiper Sandler
Overweight$42+307.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Campbell David AlanPresident and CEOJul 08 '26Option Exercise4.217,00029,470388,582Jul 10 08:00 PM
Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrJun 02 '26Sale14.034,05956,94475,941Jun 04 08:00 PM
Janeen Noel DoyleOfficerJun 02 '26Proposed Sale14.034,05956,944Jun 02 06:03 PM
Dobek MariaVice President, AccountingMay 11 '26Sale14.172,03828,87832,270May 13 08:00 PM
ANDY MEYERFormer AffiliateApr 13 '26Proposed Sale15.051,87728,246Apr 13 04:05 PM
ZACHARIAH A MCIVERFormer OfficerApr 02 '26Proposed Sale14.6574,8021,095,761Apr 02 04:02 PM
ANDY MEYERFormer AffiliateJan 26 '26Proposed Sale14.55178,7672,601,113Jan 26 04:20 PM
ANDY MEYERFormer AffiliateJan 23 '26Proposed Sale14.72118,1221,738,390Jan 23 04:08 PM
Meyer Andrew HollmanChief Business OfficerJan 02 '26Sale13.731,87925,79983,095Jan 02 09:00 PM
DiRaimondo ThomasChief Scientific OfficerJan 02 '26Sale13.732,50534,394124,425Jan 02 09:00 PM
Campbell David AlanPresident and CEOJan 02 '26Sale13.738,072110,829284,982Jan 02 09:00 PM
Winter Charles M.Chief Technical OfficerJan 02 '26Sale13.732,40132,96677,721Jan 02 09:00 PM
McIver ZachariahChief Medical OfficerJan 02 '26Sale13.732,71437,26323,286Jan 02 09:00 PM
Dobek MariaVice President, AccountingJan 02 '26Sale13.731,46220,07315,373Jan 02 09:00 PM
BYRON C ROBINSONOfficerDec 15 '25Proposed Sale15.5016,666258,366Dec 15 04:06 PM
BYRON C ROBINSONOfficerDec 08 '25Proposed Sale16.5250,000826,000Dec 08 04:42 PM
Meyer Andrew HollmanChief Business OfficerDec 01 '25Option Exercise10.593,33335,29688,307Dec 03 08:00 PM
Meyer Andrew HollmanChief Business OfficerDec 01 '25Sale32.983,333109,92984,974Dec 03 08:00 PM
BYRON C ROBINSONOfficerDec 02 '25Proposed Sale16.3863,1251,033,743Dec 02 05:15 PM
ANDREW MEYEROfficerDec 01 '25Proposed Sale34.093,333113,622Dec 01 04:20 PM
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.
PresidentDr. David Alan Campbell Ph.D.
Chief Scientific OfficerDr. Thomas Diraimondo Ph.D.
Chief Corporate & Business Development OfficerMs. Janeen Doyle
Vice President of FinanceMr. Matt Whitmire
Vice President of AccountingMs. Maria Dobek